Clinical Trial Update: Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease [Phase 2]

View source ↗

Summary

ClinicalTrials.gov listing for a Phase 2 adjuvant trial of trastuzumab deruxtecan in HER2-positive gastric cancer with persistent minimal residual disease; recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Gastric Cancer, HER2-positive Gastric Cancer | Phase 2 | Status: RECRUITING